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A B S T R A C T
Clinical use of non-steroidal anti-inﬂammatory drugs (NSAIDs) is well known to cause gastrointestinal
ulcer formation via several mechanisms that include inhibiting epithelial cell migration and mucosal
restitution. The drug-affected signaling pathways that contribute to inhibition of migration by NSAIDs
are poorly understood, though previous studies have shown that NSAIDs depolarize membrane potential
and suppress expression of calpain proteases and voltage-gated potassium (Kv) channel subunits. Kv
channels play signiﬁcant roles in cell migration and are targets of NSAID activity in white blood cells, but
the speciﬁc functional effects of NSAID-induced changes in Kv channel expression, particularly on cell
migration, are unknown in intestinal epithelial cells. Accordingly, we investigated the effects of NSAIDs
on expression of Kv1.3, 1.4, and 1.6 in vitro and/or in vivo and evaluated the functional signiﬁcance of loss
of Kv subunit expression. Indomethacin or NS-398 reduced total and plasma membrane protein
expression of Kv1.3 in cultured intestinal epithelial cells (IEC-6). Additionally, depolarization of
membrane potential with margatoxin (MgTx), 40 mM K+, or silencing of Kv channel expression with
siRNA signiﬁcantly reduced IEC-6 cell migration and disrupted calpain activity. Furthermore, in rat small
intestinal epithelia, indomethacin and NS-398 had signiﬁcant, yet distinct, effects on gene and protein
expression of Kv1.3, 1.4, or 1.6, suggesting that these may be clinically relevant targets. Our results show
that inhibition of epithelial cell migration by NSAIDs is associated with decreased expression of Kv
channel subunits, and provide a mechanism through which NSAIDs inhibit cell migration and may
contribute to NSAID-induced gastrointestinal (GI) toxicity.
ã 2015 Elsevier Inc. All rights reserved.
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NSAIDs are commonly used for their analgesic, anti-inﬂamma-
tory, and anti-pyretic activities. Though undeniably effective, use
of NSAIDs is also associated with a suite of negative, off-target
effects, including cardiovascular, renal, and gastrointestinal (GI)
toxicity [1,2]. As many as 30 million people use NSAIDs every day in
the United States alone, and nearly 25% of cases of all adverse drug
reactions are associated with NSAID use [3].
Of particular concern is the rate at which NSAIDs, both
prescription and over-the-counter, cause GI toxicity in both
humans and other species [3–5]. Estimates suggest that as many
as 50% of people taking NSAIDs daily are symptomatic of NSAID-
induced GI toxicity [6], which ranges from simple dyspepsia to
erosion, ulceration, bleeding, and death [5,7–9].* Corresponding author at: Department of Anatomy and Physiology, Kansas State
University, 1620 Denison Avenue, 228 Coles Hall, Manhattan, KS 66506, United
States.
E-mail address: ksilver@ksu.edu (K. Silver).
http://dx.doi.org/10.1016/j.bcp.2015.10.017
0006-2952/ã 2015 Elsevier Inc. All rights reserved.NSAID-induced GI toxicity has typically been associated with
non-speciﬁc inhibition of cyclooxygenase (COX) isoforms, with
NSAIDs being labeled as speciﬁc for either isoform 1 or 2 or non-
speciﬁc. Whereas there is little doubt that NSAIDs inhibit COX
activity and suppress prostaglandin (PG) production, there is
signiﬁcant evidence that COX-independent mechanisms are
involved in inducing GI toxicity [5,10]. Other mechanisms that
have been proposed to contribute to NSAID-induced GI toxicity
include altering intestinal microﬂora, interfering with neutrophil
recruitment, uncoupling of oxidative phosphorylation, decreasing
rates of apoptosis, depolarizing membrane potential, and inhibit-
ing cell migration or epithelial restitution [11–18].
Epithelia of the GI tract form a vital barrier to the noxious and
pathogenic contents of the intestinal lumen. Damage to the
epithelia must be repaired quickly and efﬁciently to prevent
further erosion or invasion by microﬂora. Epithelial restitution is
the cell migration-dependent repair modality wherein the
epithelial barrier is restored within minutes to hours of wounding
[19]. Migration also occurs under normal conditions where
epithelial cells migrate from the intestinal crypts where they
originate and cell division is actively occurring, up the long axis of
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slough off into the lumen [20–25]. Previous studies have
established that treatment with NSAIDs inhibits cell migration
and epithelial restitution through a variety of pathways, including
depolarization of Em, disruption of calpain protease signaling, and
suppression of expression of voltage-gated potassium channels
(Kv) [14,15,17,18,26–28], and that this may be one mechanism
through which NSAIDs cause GI toxicity.
There are many different components that serve vital roles
during cell migration, including a diverse array of ion channels
[29,30]. Kv channels, in particular, are necessary components of the
migration machinery [18,31]. Kv channels are involved in cell
migration and wound healing both by conducting current and/or
physically interacting with cytoskeletal or integral membrane
proteins, with Kv1.3 fulﬁlling particularly important roles.
Kv1.3 channels, which represent as much as 50% of the Kv channel
population in epithelial cells [32], make signiﬁcant contributions
to maintaining membrane potential (Em) [33,34], regulating cell
volume, and interacting with speciﬁc adhesion molecules like
b1 integrins [35], all of which are integral to the process of cell
migration (reviewed in Refs. [29,30]).
NSAIDs have been shown to affect the function or expression of
Kv channels, including Kv1.3, 1.4, 1.5, and 1.6 channels [18,33,
36–38] (reviewed in Ref. [39]). Speciﬁcally, NSAIDs with ulcero-
genic potential (indomethacin and NS-398), but not non-ulcero-
genic NSAIDs (SC-560), decrease total and surface expression of
Kv1.4 and surface expression of Kv1.6 in IEC-6 cell monolayers, and
it was suggested that this loss of expression inhibited cell
migration and caused depolarization of Em [18]. Further, re-
examination of data from a previous study [15] which used
microarray technology to identify novel targets of NSAID activity in
cultured intestinal epithelial cells (IEC-6) suggested that NS-398
suppressed mRNA expression of Kv1.3 (3.183 fold).
Given the important roles Kv channels play in cell migration and
maintenance of Em, and that NSAIDs have been shown to affect Em
and Kv channel expression in white blood cells and epithelial cells,
we decided to evaluate the effect of loss of Kv channel expression
(Kv1.3, 1.4, or 1.6) on Em and cell migration and attempt to identify
the mechanism(s) that leads from depolarization of Em to
inhibition of cell migration. Accordingly, we examined the effects
of indomethacin (a non-speciﬁc COX inhibitor), NS-398 (an
experimental COX2-speciﬁc inhibitor), or SC-560 (an experimental
COX1-speciﬁc inhibitor) treatment on Kv1.3 expression in IEC-
6 cells and the effects of inhibition of Kv1.3, 1.4, and 1.6 channel
expression on cell migration and Em in cultured IEC-6 cells.
Additionally, we examined the effect of oral NSAID treatment on
Kv1.3, 1.4, and 1.6 expression in rat small intestine. Our results
clearly showed that expression of Kv1.3, 1.4 and 1.6 was altered by
NSAID activity in vitro and in vivo, and that suppression of
expression or pharmacological inhibition of these channels
resulted in depolarization of Em and inhibition of cell migration.
Finally, we also propose a novel mechanism in which NSAIDs
disrupt calpain protease signaling and inhibit cell migration by
suppressing Kv channel expression and depolarizing Em. Our
results suggest that alteration of Kv channel expression contributes
not only to the anti-inﬂammatory effects of NSAIDs, as previously
suggested [33,36], but also may contribute signiﬁcantly to cell
migration and wound healing and/or NSAID-induced toxicity in
the GI tract.
2. Materials and methods
2.1. Reagents
IEC-6 cells (passage 13) and Dulbecco’s Modiﬁed Eagle’s Media
(DMEM) were purchased from American Type Culture Collection(ATCC, Manassas, VA, USA). Fetal bovine serum, insulin, and
gentamicin were acquired from Life Technologies (Carlsbad, CA,
USA). Indomethacin was purchased from Sigma (St. Louis, MO,
USA) and NS-398 (N-[2-(cyclohexyloxy)-4-nitrophenyl]-methane-
sulfonamide) and SC-560 (5-(4-chlorophenyl)-1-(4-methoxy-
phenyl)-3-(triﬂuoromethyl)-1H-pyrazole) were purchased from
Cayman Chemical (Ann Arbor, MI, USA). Margatoxin (MgTX) was
purchased from Alomone Labs (Jerusalem, Israel). DiBAC4(3) (bis-
(1,3-dibutylbarbituric acid)trimethine oxonol) and BOC-LM-CMAC
(7-amino-4-chloromethylcoumarin, tert-butoxycarbonyl-L-leucyl-
L-methionine amide) were purchased from Life Technologies
(Grand Island, NY).
2.2. Cell culture
The IEC-6 cell line, developed by Quaroni et al. [40], are an
undifferentiated epithelial cell line derived from rat small
intestine. Cells, cultured as described previously [15,41], were
grown in DMEM supplemented with 5% fetal bovine serum, insulin
(10 mg/mL), and gentamicin (50 mg/mL) at 37 C with 5% CO2.
Passages 15–20 were used for the purposes of this study.
For measuring the effects of NSAID treatment on cell migration
and Kv1.3 protein expression, IEC-6 cells were cultured on collagen
I-coated plates (Corning, Charlotte, NC) and treated for 72 h with
indomethacin (100 mM), NS-398 (100 mM), or SC-560 (1 mM), or
for 24 h with 10 nM MgTx (margatoxin). These drug concentrations
are consistent with measurements of tissue and plasma concen-
trations associated with their use, effectively inhibit production of
prostaglandins, do not reduce viability or induce apoptosis in
cultured IEC-6 cells, and inhibit migratory behavior of IEC-6 cells
(except for SC-560) as has been discussed previously [18]. 40 mM
K+ media was created as previously published [18] by combining
DMEM with Ham’s F12 media in a 50/50 mixture (standard IEC-
6 media contains 4 mM K+).
2.3. Nucleofection
IEC-6 cells (1.5 106 per reaction) were nucleofected with
20 pmol of non-targeting sequence #1 or Kv1.3, Kv1.4, or
Kv1.6 OnTargetplus SMARTpool siRNAs (GE Dharmacon, Lafayette,
CO) using a Nucleofector 2b Device (Lonza, Walkersville, MD) and
Cell Line Nucleofector Kit V (Lonza) using program U-031 as
suggested by the manufacturer’s guidelines. Cells were then
seeded onto collagen I-coated 60 mm plates and left to grow for
48 h. Cell migration assays were performed 48 h after nucleofec-
tion. Nucleofection efﬁciency using a GFP-expressing plasmid at
48 h was approximately 75%. At 48 h, Kv1.3, 1.4, or 1.6 expressions
were reduced to less than 50, 65, or 50% of control expression,
respectively.
2.4. PCR
Total RNA was isolated from rat mucosal tissue (four to ﬁve rats
per treatment group) using TRIzol reagent (Life Technologies,
Grand Island, NY) and a commercial kit (Qiagen, Valencia, CA). RNA
samples were subsequently treated with DNase I (Qiagen) to
ensure that there was no genomic DNA contamination. RNA
samples were then quantiﬁed using a Nanodrop Spectrophotome-
ter (Thermo Scientiﬁc).
Quantitative RT-PCR was performed on RNA samples using
primers speciﬁc for Kv1.3 (Forward 50-agtatatggtgatcgaagagg-30;
and Reverse 50-tgatgttgacacaggagttgg-30), 18S (Forward 50-
tcgctccaccaactaagaac-30; and Reverse 50-gaggttcgaagacgatcaga-
30), and GAPDH (Forward 50-gacatgccgcctggagaaac-30; and Reverse
50-agcccaggatgccctttagt-30) using a one-step quantitative RT-PCR
kit (Life Technologies) on a StepOne Plus real-time PCR system (Life
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were as follows: 50 C for 30 min, 95 C for 15 min, followed by
40 cycles of 95 C for 30 s, 60 C for 30 s, and 78 C for 30 s, with
ﬂuorescence recorded during the 78 C step. Expression of
Kv1.3 mRNA was then calculated relative to 18S or GAPDH
expression using the DDCt method [42]. The geometric mean of
the two changes in expression (vs. 18S and vs. GAPDH) was then
presented as the fold change in expression for Kv1.3 relative to
control in each drug treatment. Products from each of the primer
pairs were run on agarose gels and individually sequenced to
conﬁrm the presence of a single DNA product of the appropriate
size and sequence.
2.5. Immunoblotting
Whole cell lysates were obtained from IEC-6 cells or rat
intestinal mucosal tissue by sonicating in a commercial lysis buffer
containing protease inhibitors (RIPA lysis buffer, Santa Cruz
Biotechnology, Santa Cruz, CA) at 4 C. Protein concentrations of
lysates were quantiﬁed using a standard BCA assay (Thermo
Scientiﬁc) and measuring absorbance at 562 nm. Cell lysates were
separated on SDS-PAGE acrylamide gels and transferred to
nitrocellulose membranes. Membranes were blocked with 5%
non-fat dry milk (Bio-Rad, Hercules, CA) plus Tween-20 (0.1%,
Sigma–Aldrich, St. Louis, MO) in Tris-buffered saline (Bio-Rad) and
probed with appropriate primary and secondary antibodies. The
anti-Kv1.3, Kv1.4, or Kv1.6 (1:250, Alomone Labs, Jerusalem, Israel)
and anti-actin (1:2000, Sigma–Aldrich) primary and secondary
(conjugated to horse radish peroxidase; Santa Cruz Biotechnology)
antibodies were obtained commercially. Immunocomplexes were
detected using chemoluminescence (SuperSignal West Femto
Maximum Sensitivity Substrate, Thermo Scientiﬁc). Equal loading
of lanes was ensured by stripping and re-probing membranes with
an antibody for actin and/or photographing the gel stained with a
commercially available protein stain (Gelcode Blue, Thermo
Scientiﬁc). Densitometry analysis using imaging software
(AlphaEaseFc, AlphaInnotech, San Leandro, CA) was performed
to compare Kv1.3, Kv1.4, or Kv1.6 protein expression, normalized to
actin or gel staining, between treatment groups. Experiments
evaluating Kv1.3 expression in vitro were replicated at least four
times. Immunoblot results for Kv1.3, 1.4, and 1.6 expression in vivo
(duodenum, jejunum, ileum) were based on whole cell lysates
obtained from at least four individual rats per treatment group.
2.6. Luminometry
Analysis of surface expression of Kv1.3 was performed as
previously described [43,44]. Brieﬂy, cells were ﬁxed in 4%
paraformaldehyde (20 min), washed, and blocked with fetal bovine
serum (1%). Cells were then probed with anti-Kv1.3 primary
antibody speciﬁc to an extracellular epitope (1:50, Alomone) and a
secondary antibody conjugated to horse radish peroxidase.
Chemiluminescence was detected using a 20/20n Luminometer
(Turner Biosystems, Sunnyvale, CA) following application of
SuperSignal West Femto Maximum Sensitivity substrate (Thermo
Scientiﬁc) to cells. Plates were scraped and whole cell lysates were
collected in RIPA lysis buffer, and quantiﬁed using a BCA assay
(Thermo Scientiﬁc). Luminometry results were then normalized to
protein content (mg/mL) and then to control to permit simple
comparisons. Experiments were repeated at least three times.
Control experiments using an antibody speciﬁc to actin (Sigma) in
conjunction with a secondary antibody conjugated to horse radish
peroxidase (the same as that used for Kv1.3 experiments) did not
result in greater luminescence than using the secondary antibody
alone, indicating that we were measuring surface-speciﬁc expres-
sion of Kv1.3 protein.2.7. Migration studies
Migration studies were performed as previously described
[15,18,27]. Brieﬂy, cells were seeded onto collagen I-coated 60 mm
plates (Corning) and treated for 24 h with 10 nM MgTX prior to
wounding. Cells nucleofected with Kv channel siRNA were seeded
onto 60 mm plates and incubated for 48 h prior to wounding. A
razor blade was used to create a scratch line and remove about one-
quarter of the monolayer. Photographs were taken immediately
following wounding (to verify the quality of the scratch line) and at
6 h post wounding. Relative cell migration was quantiﬁed by
measuring the percentage of a standardized region of interest
(600 sq mm), positioned at the scratch line, occupied by migrating
cells. Photographs of three separate ﬁelds were taken per plate, and
the experiment was repeated at least three times. Results were
then normalized to the appropriate control: MgTX to control
(phosphate buffered saline vehicle), or Kv1.3, Kv1.4, or Kv1.6 siRNA
to non-targeting siRNA.
2.8. Calpain activity assays
Calpain activity assays were performed as previously de-
scribed [28,45]. Brieﬂy, calpain activity was assayed using the
BOC-LM-CMAC substrate (Life Technologies). IEC-6 cells were
seeded onto 35 mm collagen-coated plates with an optical quality
insert on the bottom of the dish (Matek, Ashland, MA) and treated
with NSAIDs (100 mM NS-398) for 48 h or MgTx (10 nM) or 40 mM
K+-containing media for 24 h prior to assay. IEC-6 cells nucleo-
fected with Kv channel siRNA were seeded onto Plates 48 h prior
to imaging. Cells were incubated with BOC-LM-CMAC (25 mM) for
20 min and then washed two times with phosphate buffered
saline. Fluorescence associated with calpain activity was then
observed on a Carl Zeiss 510 META confocal microscope (Carl Zeiss
Microscopy, Thornwood, NY) under the 40X objective (oil
immersion). Images were processed using the Zen 2012 (Blue
Edition, Carl Zeiss Microscopy). ImageJ software (http://imagej.
nih.gov/ij/) was used to measure the mean ﬂuorescence of
individual cells (20–50) from at least three different ﬁelds per
plate and three plates for each treatment group. Mean ﬂuores-
cence intensity was calculated for each ﬁeld, and these values
were used to calculate the average intensity of ﬂuorescence
associated with each treatment.
In addition to measurement with confocal microscopy, calpain
activity was also measured using a high-throughput method in a
96-well, black-sided plate (tissue culture treated, Corning). Cells
were seeded onto the 96-well plates and treated as in the 60 mm
plate assays. BOC-LM-CMAC was applied as before, and ﬂuores-
cence was measured (351/433; excitation/emission) on a Spec-
traMax i3 multi-mode detection platform with an attached
MiniMax imager (Molecular Devices, Sunnyvale, CA). A photo-
graph, using the MiniMax imager was taken to ensure equal
conﬂuence of tested monolayers. These experiments were
repeated at least twice with 12 replicates per experiment.
2.9. Measurement of Em with DiBAC4(3)
DiBAC4(3), a voltage-sensitive, ﬂuorescent dye, was used to
measure changes in membrane potential (Em) in cultured IEC-
6 cells as previously described [18]. Brieﬂy, cells were seeded onto
96-well, black-sided plates and treated with MgTx (10 nM) or
40 mM K+-containing media for 24 h or a concentration range of
indomethacin or NS-398 for 48 h. DiBAC4(3) (2 mM) in 1 X
phosphate-buffered saline or phenol red-free DMEM was applied
and cells were incubated for 30 min prior to measuring ﬂuores-
cence at 490/516 (excitation/emission) on a SpectraMax i3 multi-
mode detection platform with an attached MiniMax imager
Fig. 1. NSAIDs inhibit Kv1.3 protein expression in IEC-6 cells. (A) Exemplar blots showing bands for Kv1.3 (80 kDa) and actin (40 kDa). (B) Relative expression of Kv1.3 in whole
cell lysates isolated from IEC-6 cells treated with NSAIDs for 72 h. * indicates a signiﬁcant difference from control (p < 0.05). n = 4 per treatment group.
Fig. 2. NSAIDs inhibit surface expression of Kv1.3 protein. Relative surface
expression of Kv1.3 in IEC-6 cells treated with NSAIDs [control (n = 6), 100 mM
indomethacin (n = 3), 100 mM NS-398 (n = 3), or 1 mM SC-560 (n = 6)] for 72 h. An
antibody speciﬁc for an extracellular epitope of Kv1.3 was used to assess surface
expression with luminometry. * indicates a signiﬁcant difference from control
(p < 0.05).
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were seeded onto 96-well, black-sided plates and incubated for
48 h, then tested as above with DiBAC4(3) 48 h. These experiments
were repeated at least twice each with 12–16 replicates per
experiment.
2.10. In vivo studies
Male Wistar rats (12 wks old, 350 g each, ﬁve per treatment
group) were treated orally with indomethacin or NS-398 (10 mg/kg,
daily by gavage) for 72 h. Sections of small intestine (duodenum,
jejunum, and ileum) were isolated, lavaged, and mucosal scrapings
were made using a scalpel blade. Samples were collected for mRNA
and protein expression analysis. In addition, portions of duodenum
were also ﬁxed in 10% formalin, and embedded in parafﬁn by the
Kansas State Veterinary Diagnostic Laboratory (KSVDL) for later
sectioning and analysis with confocal microscopy. All animals were
treated in accordance with established Institutional Animal Care and
Use Committee protocols.
2.11. Confocal imaging
The KSVDL sectioned, deparafﬁnized, and performed antigen
recovery (heat and EDTA) on duodenal sections for staining using
standard practices. Duodenal sections were then blocked with 5%
fetal bovine serum in phosphate-buffered saline containing 1%
Triton-X and stained with a commercial antibody (Alomone) for an
external epitope of Kv1.3. Secondary antibody conjugated to
AlexaFluor-594 (Life Technologies) was used to probe for the
Kv1.3 antibody. Fluorescence associated with Kv1.3 was then
observed on a Carl Zeiss 700 confocal microscope (Carl ZeissMicroscopy) under the 40X objective (oil immersion). Images were
processed using the Zen 2012 (Blue Edition, Carl Zeiss Microscopy).
ImageJ software (http://imagej.nih.gov/ij/) was used to measure
the mean ﬂuorescence in epithelial cells from at least 10 distinct
areas of each ﬁeld. The experiment was repeated three times with
at least three ﬁelds captured per experiment.
Fig. 3. IEC-6 cell migration is inhibited by suppression of Kv channel expression. Cells were nucleofected with non-targeting (A), Kv1.3 (B), Kv1.4 (C), or Kv1.6 (D) siRNA 48 h
prior to wounding, and microphotographs were taken 6 h after wounding. (E) Percent migration of IEC-6 cells following treatment and wounding as determined by measuring
the percentage of a standardized region of interest covered by cells (n = 9 for each treatment). * indicates a signiﬁcant difference from non-targeting siRNA (p < 0.05).
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Fig. 4. IEC-6 cell migration is inhibited by pharmacological inhibition of
Kv1.3 channels. Cells were treated with 10 nM MgTx for 24 h prior to wounding,
and microphotographs of control (A) and MgTx-treated (B) cells were taken 6 h after
wounding. (C) Percent migration of IEC-6 cells following treatment and wounding
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Signiﬁcant differences (p < 0.05) between treatment groups
were determined using a one-way analysis of variance (ANOVA)
with a post hoc least signiﬁcant difference test when there were two
or more treatments to compare with control. When only a single
treatment was compared to control, a Student’s t-test was used
instead (e.g., migration experiments comparing MgTx vs. control).
3. Results
3.1. NSAIDs decreased Kv1.3 protein expression in IEC-6 cells
Analysis of gene expression in IEC-6 cells showed no effect of
NSAID treatment (72 h) on gene expression of Kv1.3 (data not
shown). However, we also evaluated the effects of NSAID
treatment on Kv1.3 protein expression in IEC-6 cells by Western
blot. Treatment of monolayers of IEC-6 cells with indomethacin or
NS-398 (100 mM) for 72 h resulted in signiﬁcant decreases in
Kv1.3 protein in whole cell lysates, whereas SC-560 (1 mM) had no
effect (Fig. 1).
3.2. NSAIDs decreased surface expression of Kv1.3 in IEC-6 cells
Typically, Kv1.3 channels are expressed in plasma membrane,
and it is in this location that they are functionally relevant to cell
migration. Therefore, we determined the effect of NSAID treatment
on plasma membrane expression of Kv1.3 channels via luminom-
etry. Treatment of monolayers of IEC-6 cells with indomethacin
(100 mM), NS-398 (100 mM), or SC-560 (1 mM) for 72 h reduced
chemiluminescence in paraformaldehyde-ﬁxed cells probed with
an anti-Kv1.3 antibody speciﬁc to an extracellular epitope (Fig. 2).
Control experiments using an antibody speciﬁc to actin in
conjunction with a secondary antibody conjugated to horse radish
peroxidase (identical to that used for Kv1.3 detection) did not result
in greater luminescence than using the secondary antibody alone
(data not shown), strongly suggesting that signal that was detected
for Kv1.3 was wholly surface-based.
3.3. Silencing of Kv channel expression or blocking of Kv channels
inhibited cell migration
NSAIDs have previously been shown to cause signiﬁcant
decreases in not only Kv1.3 expression, but also Kv1.4 and
Kv1.6 in IEC-6 cells [18]. Therefore, we were interested to see if
loss of Kv channel expression results in inhibition of cell migration
as has been proposed (though not directly shown). Accordingly, we
nucleofected IEC-6 cells with pools of siRNA speciﬁc to Kv1.3, Kv1.4,
or Kv1.6, and tested to see if migration was inhibited following
silencing of Kv channel expression (Fig. 3). Inhibition of Kv1.3, Kv1.4,
or Kv1.6 expression with siRNA was sufﬁcient to signiﬁcantly
inhibit cell migration at 6 h post wounding (Fig. 3).
Subsequently, we also evaluated the effect of MgTx (10 nM), a
Kv1.3 and 1.6 channel blocker, on migration of IEC-6 cells (Fig. 4).
Not surprisingly, MgTx effectively inhibited migration of IEC-6 cells
at 6 h post wounding (Fig. 4C).
3.4. Silencing of Kv channel expression or inhibition of
Kv1.3 depolarizes Em
Previous efforts showed that inhibition of cell migration by
NSAIDs was associated with depolarization of Em and suggestedas determined by measuring the percentage of a standardized region of interest
covered by cells (n = 12 for each treatment group). * indicates a signiﬁcant difference
from control (p < 0.05).
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cause [18]. Accordingly, we silenced Kv1.3, 1.4, or 1.6 protein
expression using siRNA (Fig. 5A) or inhibited Kv channel activity
using 10 nM MgTx or simulated Kv channel closure with media
containing 40 mM K+ (Fig. 5B) and measured changes in membrane
potential using the oxonal voltage-sensitive dye, DiBAC4(3).
Suppression of Kv channel expression with siRNA signiﬁcantly
increased ﬂuorescence of DiBAC4(3), indicating that the Em of IEC-
6 cells was depolarized (Fig. 5A). Similarly, MgTx (10 nM) and
media containing 40 mM K+ were also effective at increasing
DiBAC4(3) ﬂuorescence (Fig. 5B), indicating that Kv1.3, 1.4, and
1.6 contribute to maintenance of Em in IEC-6 cells.
Previous experiments also established that indomethacin and
NS-398 inhibit cell migration in IEC-6 cells over a range of
concentrations (1–100 mM) [15], so we decided to also evaluate the
concentration range over which these NSAIDs also depolarize Em.
We treated IEC-6 monolayers with concentrations of indomethacin
or NS-398 ranging between 0.01 and 100 mM for 48 h and then
measured depolarization of Em with DiBAC4(3) (Fig. 5C and D).
Indomethacin caused a concentration-dependent increase in
DiBAC4(3) ﬂuorescence that was statistically signiﬁcant at every
concentration tested except for 0.01 mM (Fig. 5C). NS-398 causedFig. 5. Depolarization of Em by Kv channel siRNA, 40 mM K+-containing media, NSAIDs, or
cells nucleofected with non-targeting (n = 10), Kv1.3 (n = 12), Kv1.4 (n = 12), or Kv1.6 
depolarization of Em. (B) Increased DiBAC4(3) ﬂuorescence in IEC-6 cells treated with
measurement. (C and D) Increased DiBAC4(3) ﬂuorescence in IEC-6 cells treated wit
respectively for 48 h. * indicates a signiﬁcant difference from non-targeting siRNA (p <modest, yet signiﬁcant, increases in ﬂuorescence at concentrations
from 0.1 to 10 mM (Fig. 5D). Unfortunately, we were not able to
accurately measure depolarization of Em at 100 mM NS-398 with
DiBAC4(3) in this study; however, previous studies have shown
with both voltage-sensitive dyes and sharp electrode recording
that 100 mM NS-398 depolarizes Em in IEC-6 cells [18].
3.5. Depolarization of Em inhibits calpain protein expression and
calpain activity
Previous studies have shown that NSAIDs inhibit migration of
IEC-6 cells by disrupting the expression and activity of calpain
proteases [28], and we were interested to determine if there was a
connection between depolarization of Em and calpain expression
or activity. Therefore, we treated monolayers of IEC-6 cells with
40 mM K+ media (24 h) or NS-398 (100 mM, 72 h) to induce
depolarization of Em. Both 40 mM K+ and NS-398 caused signiﬁcant
reductions in expression of calpain 1 and 2 protein (Fig. 6A and B).
Subsequently, we used the calpain substrate, BOC-LM-CMAC, to
evaluate the effects of decreases in Kv channel expression or
function or Em depolarization on calpain activity (Figs. 7 and 8).
Treatment of IEC-6 monolayers with siRNA speciﬁc to Kv1.3 pharmacological inhibition of Kv1.3 with MgTx. (A) DiBAC4(3) ﬂuorescence in IEC-6
(n = 12) siRNA 48 h prior to Em measurement. Increased ﬂuorescence indicates
 40 mM K+-containing media (n = 12) or 10 nM MgTx (n = 12) for 24 h prior to Em
h varying concentrations of indomethacin or NS-398 (n = 16 per concentration),
 0.05) or control (p < 0.05).
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ﬂuorescence associated with calpain activity when compared with
cells nucleofected with non-targeting siRNA (Fig. 7A and E).
Similarly, use of a high-throughput method in a 96-well plate also
revealed signiﬁcant decreases in ﬂuorescence associated with
calpain activity (Fig. 7F).
Consistent with these ﬁndings, methods that cause depolariza-
tion of Em in IEC-6 cells (Fig. 5A) also resulted in deﬁcits in calpain
activity (Fig. 8). Treatment of IEC-6 cells with NS-398 (48 h, Fig. 8E),
40 mM K+ media (24 h, Fig. 8B), or 10 nM MgTx (24 h, Fig. 8C)
decreased ﬂuorescence associated with calpain activity when
compared to their appropriate controls (Fig. 8A, D, and F).
3.6. NSAIDs altered mRNA and protein expression of Kv channels in rat
small intestine
Our results with the IEC-6 cell line suggested that Kv1.3 was a
target of NSAID activity in vitro, but we wanted to determine if
Kv1.3 expression would also be affected in vivo. Accordingly, rats
were treated orally with vehicle control, indomethacin (10 mg/kg),
or NS-398 (10 mg/kg) for 72 h, and mucosal tissue was harvested
from duodenum, jejunum, and ileum following treatment. Analysis
of mRNA expression, normalized to both 18S and GAPDH
expression, revealed varying effects of NSAID treatment on
Kv1.3 expression throughout the small intestine (Fig. 9A). In
duodenum and ileum, indomethacin signiﬁcantly increased
Kv1.3 mRNA expression, but had no effect on gene expression of
Kv1.3 in mucosal tissue of jejunum. In contrast, NS-398 caused aFig. 6. Effect of depolarization of Em by 40 mM K+-containing media or NS-398 on the rela
treatment) in IEC-6 cells. Right panels show exemplar blots for calpain 1 (80 kDa, uppe
from control (p < 0.05).signiﬁcant decrease in Kv1.3 gene expression in jejunum, but had
no signiﬁcant effect on Kv1.3 gene expression in ileum. The
apparent reduction in Kv1.3 expression in duodenum was not
statistically signiﬁcant largely due to the high variability in the
fold-change in gene expression caused by indomethacin in the
duodenum.
Testing of whole cell lysates isolated from mucosa from rat
small intestine also showed variability in effects on Kv1.3 protein
expression following oral treatment with NSAIDs (Fig 9B).
Kv1.3 protein expression was signiﬁcantly inhibited by treatment
with indomethacin or NS-398 in both duodenum and ileum, but
was unaffected in jejunum by either NSAID.
Subsequent experiments using confocal microscopy to localize
Kv1.3 protein expression in the villi from rat duodenum revealed
that Kv1.3 is expressed throughout the villi, in both epithelial and
subepithelial tissue (Fig 10A). Oral treatment of rats with
indomethacin (Fig. 10B) or NS-398 (Fig. 10C) resulted in a
substantial reduction in ﬂuorescence associated with
Kv1.3 expression (Fig. 10D).
As with Kv1.3, we also evaluated the effects of oral NSAID
treatment on protein expression of Kv1.4 (Fig. 11A) and Kv1.6
(Fig. 11B) in rat small intestine. Interestingly, indomethacin only
signiﬁcantly reduced Kv1.4 protein expression in duodenum,
though there was a trend for decreased Kv1.4 expression in
jejunum and ileum as well (Fig. 11A). In contrast, indomethacin
signiﬁcantly reduced Kv1.6 expression throughout the mucosa of
the small intestine (Fig. 11B). NS-398 did not signiﬁcantly reduce
expression of Kv1.4 or 1.6 in any of the three sections of smalltive protein expression of calpain 1 (A; n = 3 for each treatment) or 2 (B; n = 7 for each
r), calpain 2 (80 kDa, lower), or actin (40 kDa). * indicates a signiﬁcant difference
Fig. 7. Effect of suppression of Kv channel expression on calpain activity in IEC-6 cells. Cells were nucleofected with non-targeting (A), Kv1.3 (B), Kv1.4 (C), or Kv1.6 (D) siRNA
48 h prior to measurement of ﬂuorescence of BOC-LM-CMAC using confocal microscopy. (E) Measurement of mean intensity of BOC-LM-CMAC ﬂuorescence and calpain
activity in confocal experiments (n = 7 per treatment). (F) Measurement of calpain activity with the BOC-LM-CMAC ﬂuorescence assay using a high-throughput 96-well plate
method 48 h after nucleofection (n = 12 for each treatment group). * indicates a signiﬁcant difference from non-targeting siRNA (p < 0.05).
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duodenum and jejunum, NS-398 appeared to reduce
Kv1.6 expression, though this effect was not signiﬁcant, likely
due to the large variation in protein expression found with NS-398
(Fig. 11B).
4. Discussion
NSAIDs enhance ulcer formation and delay healing by disrupt-
ing cell migration and epithelial restitution [14,17,26]. Previous
studies have shown that NSAIDs with ulcerogenic potential inhibit
cell migration in cultured IEC-6 cells through several mechanisms,
including depolarization of Em, disruption of calpain signaling
pathways, and inhibition of growth factor expression [15,27,28]. In
addition, NSAIDs suppressed the total expression of Kv1.4 and the
surface expression of Kv1.4 and Kv1.6 channels, an effect which is
consistent with depolarization of Em [18].
Kv channel expression and activation is an important compo-
nent of IEC-6 cell migration machinery [31,46,47]. Our results are
in agreement with these previous studies and clearly demon-
strate that inhibition of Kv1.3, 1.4, or 1.6 channel expression by
NSAIDs is sufﬁcient to depolarize membrane potential and inhibit
cell migration as demonstrated by silencing protein expression
with siRNA, pharmacological inhibition of Kv channels with MgTx,
or artiﬁcial depolarization of Em with elevated extracellular K+.
Interestingly, total protein expression of Kv1.3 and 1.4 and surface
expression of Kv1.6 [18] were decreased following treatment withFig. 8. Effect of NSAIDs, 40 mM K+-containing media, or MgTx on calpain activity in IEC-6
or control (C; PBS), 40 mM K+-containing media (D) or 10 nM MgTx (E) for 24 h prior 
Measurement of mean intensity of BOC-LM-CMAC ﬂuorescence and calpain activity in c
non-targeting siRNA (p < 0.05).indomethacin or NS-398, NSAIDs with signiﬁcant ulcerogenic
potential, whereas SC-560, an NSAID lacking ulcerogenic poten-
tial at the concentrations tested, did not. These results, in
particular, are supportive of the hypothesis that suppression of Kv
channel expression is an important contributor to Em in IEC-
6 cells, NSAID-induced inhibition of cell migration, and/or
possibly GI toxicity.
Surprisingly, SC-560 (COX1-speciﬁc inhibitor), like indometha-
cin (non-speciﬁc COX inhibitor) and NS-398 (COX2-speciﬁc
inhibitor), reduced surface expression of Kv1.3; a result that is
contradictory to our hypothesis of the inhibition of cell migration
by NSAIDs with ulcerogenic potential. Our only current explan-
ations for this discrepancy are to suggest that either total protein
expression of Kv1.3 is sufﬁcient for proper cell migration or that the
inhibition of surface expression of Kv1.3 by SC-560 was insufﬁcient
to interfere with cell migration. Alternatively, reductions in
expression of multiple Kv channels (SC-560 only appears to affect
Kv1.3, not Kv1.4 or Kv1.6 [18]) or suppression of total Kv1.3 protein
may be necessary for NSAIDs to disrupt cell migration. The
necessity of reducing total expression of Kv1.3 is consistent with
our siRNA data where inhibition of total expression of any of the Kv
channels tested was sufﬁcient for inhibition of cell migration. In
any case, the effect of SC-560 on surface, but not total expression of
Kv1.3, and why this does not inhibit cell migration, requires more
investigation.
Indomethacin and NS-398 have previously been shown to
inhibit migration of IEC-6 cells over a range of concentrations from cells. Cells were treated with control (A; 0.1% DMSO) or 100 mM NS-398 (B) for 48 h
to measurement of ﬂuorescence of BOC-LM-CMAC using confocal microscopy. (F)
onfocal experiments (n = 4 per treatment). * indicates a signiﬁcant difference from
Fig. 9. NSAIDs alter expression of Kv1.3 mRNA and protein in rat small intestine. (A)
Relative expression of Kv1.3 mRNA in duodenum, jejunum, and ileum as determined
by the DDCt method. n = 5 for control and NS-398 and n = 4 for indomethacin for
each section of small intestine. (B) Relative expression of Kv1.3 protein in duodenum
(n = 4 for each treatment group), jejunum (n = 5 for each treatment group), and
ileum (n = 7 for each treatment group), in addition to exemplar blots showing bands
for Kv1.3 (80 kDa) and actin (40 kDa). * indicates a signiﬁcant difference from control
(p < 0.05).
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of Em in IEC-6 cells (Fig. 5C and D) was consistent with the
previously reported cell migration data (signiﬁcant depolarization
or inhibition of migration from 1 to 100 mM indomethacin or
NS-398) and suggest that depolarization of Em may be a primary
mechanism for inhibiting cell migration in IEC-6 cells.
This is the ﬁrst report showing that potassium channel
expression in intestinal epithelial cells of rats is altered by
treatment with NSAIDs in vivo. Similar to our in vitro results, oraltreatment of rats with indomethacin or NS-398 caused signiﬁcant
reductions in Kv1.3 protein expression in duodenum and ileum.
Further, NSAID treatment caused signiﬁcant suppression of
Kv1.6 expression throughout small intestinal mucosa as well as
in reductions in Kv1.4 protein expression in duodenum. Given the
importance of Kv channels, particularly Kv1.3 [35,48], in epithelial
cell migration [29,30], our results are consistent with the
hypothesis that inhibition of Kv channel expression may be a
mechanism through which NSAIDs inhibit cell migration in vivo in
stomach [16,17] or small intestine (unpublished results).
Interestingly, indomethacin or NS-398 affected mRNA expression
differently than protein expression in rat small intestine. In
duodenum, for example, where NS-398 treatment reduced, though
not signiﬁcantly, mRNA expression of Kv1.3, indomethacin caused a
sharp increase in mRNA expression, even though Kv1.3 protein
expression for each treatment was signiﬁcantly reduced. Similar
discrepancies were also observed in jejunum and ileum. Given the
large number of regulatory steps that can occur between mRNA
transcription and translation into a protein (including, but not
limited to: post-transcriptional regulation, RNA processing, alterna-
tive splicing and differential spicing, RNA stability, and exclusion/
inclusion of regulatoryelements), it is not necessarily surprising that
there are discrepancies. Furthermore, recent insights from tran-
scriptomic and proteomic analyses suggest that mRNA abundance is
not necessarily predictive of protein abundance, particularly in a
system that is disturbed (e.g., by treatment with a drug) [49]. The
discrepancies we observed may reﬂect temporal differences in the
signaling pathways calling for changes in gene expression and
changes in protein expression, or, alternatively, may reﬂect
destruction of the Kv1.3 protein by treatment with NSAIDs resulting
in up regulation of gene expression, particularly in the case of
indomethacin in duodenum and ileum.
The importance of Kv1.3 expression and function in the immune
system has resulted in increasing attention directed at Kv1.3 as a
target for therapeutic intervention [50,51], and NSAIDs are well
known to affect Kv1.3 channels [39,52]. Diclofenac, a moderately
COX2-speciﬁc inhibitor, suppresses expression of Kv1.3 channels in
macrophages and causes changes in Em [33,36], and inhibits cell
migration and activation of macrophages and T-cell activation [36].
Our results are consistent with these, and underscore the
importance of Kv1.3 channel expression or function to potential
toxic and anti-inﬂammatory effects of NSAID treatment.
In addition to showing effects of NSAID treatment on Kv channel
expression in cultured intestinal epithelial cells and in mucosal
epithelia of rat small intestine for the ﬁrst time, our efforts
have also revealed a heretofore unrecognized mechanism through
which depolarization of Em or suppression of Kv channel
expression results in inhibition of cell migration. We demonstrated
that silencing of Kv1.3, 1.4, or 1.6 channel expression, treatment
with NSAIDs with ulcerogenic potential, inhibition of Kv channel
function with MgTx, or depolarization of Em with 40 mM K+
resulted in substantial decreases in calpain protease activity and
even calpain 1 or 2 protein expression (in the case of NS-398 or
40 mM K+). Calpains are a family of cysteine proteases that have
important functional roles in many cellular processes, including
cell migration, signal transduction, cell proliferation, and even
tumorigenesis [53–58]. Most relevant to this study, calpains are
known to cleave speciﬁc proteins involved in cellular adhesions,
permitting precise and coordinated cell locomotion [54,55,57].
Previous studies with cultured IEC-6 cells demonstrated that
NSAIDs suppress total and plasma membrane expression of
calpains 1 and 2, in addition to inhibiting calpain activity
[15,28]. Furthermore, inhibition of calpain activity by the
inhibitors, ALLM or ALLN, or NSAIDS with ulcerogenic potential
resulted in signiﬁcant deﬁcits in cell migration. Our results provide
a link between seemingly separate effects of NSAIDs, inhibition of
Fig. 10. Confocal microscopy images of reductions in Kv1.3 protein expression in duodenal villi from rats treated with control (A), indomethacin (B), or NS-398 (C). Kv1.3 (red)
is labeled with an AlexaFluor 594 conjugated antibody and nuclei (blue) are stained with DAPI. (D) Measurement of mean intensity of ﬂuorescence associated with Kv1.3
expression in confocal experiments (n = 3 per treatment). * indicates a signiﬁcant difference from non-targeting siRNA (p < 0.05).
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conceptual framework to investigate disruption of cell migration
by NSAIDs. Additionally, it is interesting to note that NSAIDs have
been observed to affect Kv1.3 channel expression, activation, and
migration in macrophages and T lymphocytes [36], and that
calpains play a signiﬁcant role in the directed chemotaxis of
neutrophils [56], further supporting the idea that depolarization of
Em, inhibition of Kv channel expression, and inhibition of calpain
activity not only potentially contribute to the anti-inﬂammatory
effects of NSAIDs, but also possibly to their toxic effects on the GI.
The compounds used in this study are a structurally diverse
group that is representative of the NSAID class in terms of
pharmacological proﬁle and tendency to cause GI toxicity.
Indomethacin is a prototypical NSAID that is an indiscriminateinhibitor of COX isoforms and has a high ulcerogenic potential,
causing ulcers in drug-treated animals [59–61]. NS-398 is an
experimental COX2-speciﬁc inhibitor that has moderate ulcero-
genic potential, not causing ulceration of the stomach upon
administration, but delaying ulcer healing [4,59–62]. SC-560, also
an experimental drug, is a speciﬁc inhibitor of COX1 that does not
inhibit cell migration or re-epithelialization of wounded cell layers
and has very low ulcerogenic potential at the concentrations used
in this study [60,63,64].
In addition to the representative nature of this group of
compounds, the concentrations and doses at which indometh-
acin, NS-398, and SC-560 were used in these experiments are
consistent with their therapeutic and experimental use by other
research groups. A concentration of 100 mM (the highest used in
Fig. 11. Effect of oral NSAID treatment on relative protein expression of Kv1.4 (A) or Kv1.6 (B) in rat small intestine (duodenum, jejunum, or ileum). Right panels (top and
bottom) show exemplar blots for Kv1.4 (80 kDa), Kv1.6 (68 kDa), or actin (40 kDa). * indicates a signiﬁcant difference from control (p < 0.05). n = 4 for each treatment group
per section of small intestine.
626 K. Silver et al. / Biochemical Pharmacology 98 (2015) 614–628this study) for indomethacin and NS-398 is capable of inhibiting
PGE2 synthesis in vitro without causing cellular toxicity in
cultured epithelial cells [4,14,61,65–67], while still maintaining
the COX2 selectivity of NS-398 [59,68–70]. In addition, 100 mM
indomethacin or NS-398 inhibits cell migration of cultured
epithelial cells [14,15,18,27,28], and is consistent with measure-
ments of tissue and plasma concentrations following therapeutic
dosing with indomethacin [71,72]. Furthermore, use of 10 mg/kg
indomethacin or NS-398 in our in vivo experiments is consistent
(or less than) doses of these drugs used in many other
experimental protocols focused on understanding either the
toxicity of NSAIDs in the GI or their ability to ameliorate
peripheral pain [60,62,73–76]. These, in conjunction with the
large foundation of data collected by our laboratory on the
molecular effects of these drugs on cultured IEC-6 cells and cell
migration [15,18,27,28,76] make these drugs ideal for studying
the toxic effects of NSAIDs on GI epithelia in our in vivo and in
vitro models. Further, the representative nature of this group of
chemicals and the therapeutic levels at which they were applied
lend clinical relevance to any effects we observed in vitro and in
vivo.Treatment with NSAIDs has been shown to affect a wide variety
of ion channels, including voltage-gated sodium channels, voltage-
gated calcium channels, potassium channels (voltage-gated,
ligand-gated, ATP-sensitive, calcium and sodium activated),
acid-sensing ion channels, transient receptor potential channels,
and anion channels [39,52]. Previous studies examining the effects
of NSAIDs on Kv channels have focused primarily on Kv1.3 channels
in immune cells, and focused on relating changes in expression and
Em to anti-inﬂammatory effects of NSAIDs [33,36,37,77]. Our
results demonstrate that NSAIDs affect Kv channel expression in a
wider array of cell types than was previously appreciated. Whereas
the effects of NSAIDs on Kv channels in immune cells (and others?)
may contribute to their anti-inﬂammatory and anti-pyretic effects,
suppression of Kv channel expression in intestinal epithelial cells is
associated with inhibition of cell migration and wound healing and
may contribute signiﬁcantly to NSAID-induced GI toxicity.
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